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Abstract
Background: To investigate the mechanisms of multidrug resistance of brain tumors, to identify the site of cellular
expression of P-gp in human brains in situ and to morphologically determine whether an association may exist
between P-gp and caveolin-1.
Methods: Immunohistochemistry was used to detect the expression and location of P-glycoprotein (P-gp),
Multidrug resistance-associated protein (MDR), Lung resistance-related protein (LRP), Topoisomerase II (Topo II) and
Glutathione-S-π (GST-π) in 30 patient tumor tissues and 5 normal brain tissues. The sections were subjected to
double labeling for P-gp (TRITC labeled) and caveolin-1 (FITC labeled). The location and characteristics of
expression of the two proteins in the blood brain barrier(BBB) was observed using a laser scanning microscope.
Results: High expression of P-gp was detected in vessel walls and the tissue surrounding the vessels. However,
expression of P-gp was low in tumor cells. The expression of the other 4 multidrug resistance proteins was not
observed in the vessel walls. Laser scanning microscopy showed P-gp and caveolin-1 co-expression: the two
proteins co-localized either in the luminal endothelial compartment or at the border of the luminal/abluminal
compartments.
Conclusion: Chemotherapeutics drugs are interrupted in the end-feet of neuroepithelial cells of the BBB by P-gp,
which weakens the chemotherapeutic effect. P-gp marks the BBB, and the transporter is localized in the luminal
endothelial compartment where it co-localizes with caveolin-1.
Introduction
Currently, primary malignant brain tumors and brain
metastases are still difficult to treat with cytotoxic
agents. Even though new chemotherapeutic schedules
have improved results of cancer treatment in other parts
of the body (e.g., small-cell lung cancer, breast cancer,
various leukemias), the efficacy of these new schedules
in brain tumors remains poor [1]. In addition to the
blood brain barrier(BBB), resistance mechanisms at the
tumor cell level may include the intrinsic chemo-insen-
sitivity of brain tumors. The BBB is a major impediment
to the entry of many therapeutic drugs into the brain,
and over the last decade, it has become clear that multi-
specific, xenobiotic transporters play a significant role at
the BBB [2]. The major determinants of drug permeabil-
ity across the BBB have long been thought to be based
solely on lipophilicity and molecular weight. Although
many anticancer drugs are highly lipophilic and rela-
tively small, the permeation level of those drugs across
the BBB is unexpectedly low [3]. This can be partially
explained by the expression of P-glycoprotein (P-gp)
[4,5]. P-glycoprotein (P-gp) is a 170-kDa transmembrane
glycoprotein that is encoded by the human multidrug-
resistance gene MDR1 and is an important functional
component of the BBB [6]. P-glycoprotein is an adeno-
sine triphosphate (ATP)-dependent pump. When the
drug enters the cells, ATP hydrolysis provides the
energy for active drug transport, enabling the transpor-
ter to function against steep concentration gradients.
The drug and ATP initially bind to the protein at their
respective binding sites, where ATP hydrolyzes to ADP
and yields energy for extrusion of the drug [7]. The
intracellular drug concentration remains at a low level,
leading to tumor cell resistance. There are two different
views about the exact location of P-gp in the BBB. One
view is that the P-gp is only at the luminal endothelial
membrane. This selective one-front localization suggests
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cytotoxic substances and drugs from the endothelial
cells back into the bloodstream [8]. Another view is that
the site of expression of P-gp is also in perivascular
astrocytes in the human brain [9,10]. Moreover, recently
studies have shown that P-gp is localized to caveolae
and co-immunoprecipitates with caveolin-1 [11], an
integral protein of the caveolae frame, suggesting that
the two proteins might physically interact.
The purpose of the present study was to examine the
mechanisms of multidrug resistance of brain tumors
and the localization of P-gp in pediatric brain tumors.
This in situ study was carried out on tumor tissues by
immunohistochemistry using a monoclonal antibody
against P-gp. In addition, double immunolabeling was
carried out with antibodies to P-gp and caveolin-1 by
immunofluorescence laser scanning confocal microscopy
to ascertain whether there is any association between
these molecules in the microvessels of brain tumors.
Materials and methods
Materials
This study included 30 samples of pediatric brain tumor
tissues, including 19 astrocytomas, 8 ependymomas,
3 medulloblastomas. The patients were 20 boys and
10 girls ranging between 6 months and 12 years (median
7.6 years) who were undergoing tumor resection without
chemotherapy for high grade (III-IV) tumors (10 cases)
and low grade (I-II) tumors (20 cases), according to the
grade of Malignancy of Brain Tumor in WHO in 2000
[12]. Five brain tissue samples from autopsies (patients
died due to cardiovascular disease) were used as
controls.
Immunohistochemistry
Paraffin sections were first rehydrated, and then rehy-
drated sections were incubated with a 1:200 dilution of
rabbit anti-human primary antibody against P-gp (Santa
C r u zB i o t e c h n o l o g y ,S a n t aC r u z ,C A ) ,L R P( A B C O M
Information Systems Pvt. Ltd, USA), MRP (Maixin Bio,
Fuzhou, China), GST-π (Maixin Bio, Fuzhou, China),
Topo II (ABCOM Information Systems Pvt. Ltd, USA),
S-100 (Santa Cruz Biotechnology, Santa Cruz, CA) or
control IgG (1:1000) overnight at 4°C. The tissue sec-
tions were washed in PBS and then incubated with a
1:100 dilution of biotinylated secondary sheep anti-rab-
bit or goat anti-rabbit IgG (Jingmei BioTech, Shenzhen,
China). After washing with PBS, tissue sections were
incubated with an avidin-biotin complex and developed
in 0.075% (w:v) 3,3 diaminobenzidine (DAB). After
lightly counterstaining with haematoxylin, the sections
were dehydrated. P-gp, MRP, LRP, GST-π are expressed
in the cell membrane and or cytoplasm, and Topo-II is
expressed in the nucleus. A positive reaction is colored
brown. The intensity of immunostaining around the
stent struts was scored as follows: 0, no staining; 1,
minor staining only; 2, moderate staining; and 3, heavy
staining. Intensities of 2 and 3 were considered strongly
positive and indicate that drug resistance would be
induced by the resistance protein. Scoring was per-
formed on every third strut in each vessel beginning
with the strut closest to the top of the slide by an inves-
tigator blinded to the treatment allocation.
Immune co-labeling of P-gp/caveolin-1
Tumor sections were first permeabilized in 0.01 M PBS
containing 0.1% Triton X-100 (PBST) for 3 × 5 min fol-
lowed by blocking in 10% goat serum in 0.01 M PBST.
Antibodies were diluted in 3% bovine serum albumin in
0.01 M PBST. The anti-caveolin-1 antibody was used at
concentrations between 0.2-5 mg/ml, and the anti-P-gp
antibody was used at a concentration of 5-10 mg/ml.
Prior to application to the tissue, the primary antibody
was pre-incubated with the blocking peptide at 37°C for
3 h (caveolin-1, Santa Cruz Biotechnology, Santa Cruz,
CA) or overnight at 4°C (P-gp). After thorough washing
steps using PBS, sections were incubated for 1 h at
room temperature with 5 mg/ml of each secondary anti-
body. Following washing with PBS, the sections were
put on coverslips.
The sections were viewed under a Leica TCS-SP2 con-
focal laser scanning microscope (Leica Instruments Co.,
Ltd. German) using ×40 and ×63 oil-immersion objec-
tive lenses with either ×1 or ×2 zoom factors. On the
double-immunolabeled sections, a sequential scan pro-
cedure was applied during image acquisition of the two
fluorophores, Alexa Fluor 488 (excitation at 488 nm and
detection range 500-535 nm; green fluorescence) and
Alexa Fluor 568 (excitation at 568 nm and detection
range 580-620 nm; red fluorescence). Confocal images
were taken at 0.5-μm intervals through the z-axis of the
section, and a total depth of 15-20 μm was covered.
Images from individual optical sections and multiple
serial optical sections were analyzed, recorded digitally
and stored as TIFF files in Adobe Photoshop software.
All the investigation procedures on human tissues
were carried out in accordance with the local institu-
tional ethical committee policies. This study were
approved by the relevant regulatory committee of the
Chongqing Medical University.
Statistical analysis
Statistical data were analyzed using the SPSS 10.03 soft-
ware (SPSS, Chicago, IL, USA). The rank sum test was
used to examine the differential expression of the 5
multidrug resistance proteins in brain tumors. Fisher
definite probability methods were used to examine the
differences between high grade and low grade tumors.
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P < 0.05.
Results
Expression of 5 multidrug resistance proteins in
brain tumors
In our study, we find the expression of multidrug resis-
tance proteins in three different positions, including
tumor cells, capillary vessels and interstitial cells.
In tumor cells, the strongly positive rate of P-gp, Topo
II, GST-π, LRP and MRP were 26.67%, 23.33%,
16.67%,3.33% and 3.33%, respectively (Tab 1). This differ-
ence was statistically significant (Rank sum test, P < 0.01),
which shows that the positive expression of the 5 multi-
drug resistance proteins in brain tumors is not identical,
and the positive expression of P-gp was observed to be the
highest.
However, in our study, the expression of P-gp is weak
in tumor cells but strongly positive in capillary vessels
(Fig 1a, b and Fig 1c). Low positive expression of LRP,
MRP, GST-π and Topo II was observed in capillary ves-
sels (Tab 2). In the normal brain tissues, the expression
of P-gp was strongly positive in the tissues surrounding
the cerebral vessels, but no positive expression was
observed in capillary vessels. The BBB contains capillary
endothelial cells, basement membrane and the end-feet
of astrocytes. The accurate structure is difficult to dis-
tinguish using ordinary light microscopy. In order to
confirm the expression of P-gp in the end-feet of astro-
cytes, the S-100 protein was used to locate the end-feet
of astrocytes by immunohistochemistry. The expression
of the S-100 protein was positive in the capillary walls
(Fig 1d). These findings suggest P-gp expression in the
microvasculature is found at both the endothelium as
well at the astrocyte end-feet at the microvasculature. In
addition, the same results were observed in the intersti-
tial cells.
Otherwise, we find the expression of resistance pro-
teins in interstitial cells are similar to the tumor cells.
The positive expression of P-gp is highest (Tab 3),
w h i c hs u g g e s t st h a tP - g pi st h em a i np r o t e i ni nt u m o r
drug resistance. The expression of P-gp in the interstitial
cells was related to the distance of the cells from the
capillary wall. The nearer the cell was to the capillary
wall, the stronger the expression of P-gp (Fig 1c).
Expression of the 5 multidrug resistance proteins in
different grade tumors
In tumor cells and interstitial cells, there was no signifi-
cant difference between the expression of the 5 multi-
drug resistance proteins (Fisher definite probability
methods, P > 0.05) between high grade and low grade
tumors (Tab 4). In the capillary vessels, the strong posi-
tive expression of P-gp was 60% (6/10) in high grade
and 10% (2/20) in low grade tumors. This difference
was statistically significant (Fisher definite probability
methods, P < 0.05) (Tab 4), which shows that the P-gp
positive rate in high grade tumors is higher than in low
grade tumors and in capillary vessels.
Double P-gp/caveolin-1 immunolabel
On the double P-gp/caveolin-1-immunolabeled samples,
observation of sections at higher magnification on serial
optical planes of cross-sectioned microvessels confirmed
that the expression of P-gp corresponded to the
endothelial cells and also revealed that the transporter is
localized in the luminal compartment of endothelial
cells (Fig 2b and Fig 2f). Unlike P-gp, caveolin-1 stained
the entire thickness of the endothelium from the lumi-
nal to the abluminal side with a finely punctate pattern
in the endothelial luminal compartment and larger
fluorescent puncta in the abluminal luminal compart-
ment (Fig 2c and Fig 2g). Comparing the single channel
signal of P-gp and caveolin-1 (green and red fluores-
cence, respectively), it is evident that both proteins are
present in the luminal compartment of the endothelial
cells. Nevertheless, the exact extent of P-gp/caveolin-1
co-localization is only revealed on the merged images,
which were obtained by superimposing the two fluores-
cent signals (Fig 2d and Fig 2h, yellow fluorescence).
P-gp and caveolin-1 most frequently co-localized in the
luminal compartment of the endothelial cells, although
elsewhere, the fluorescent signals do not appear to over-
lap completely, and co-localization was detectable only
at the boundary between the luminal and abluminal
endothelial cell compartments.
Discussion
A large number of studies have analyzed P-gp sub-
strates, expression and activities in brain tumors. Cul-
tures of cerebral endothelial cells, isolated brain
microvessels, and the P-gp knockout mouse have been
used to study the functions of P-gp. In the specific field
of the human BBB, our study contributes to the knowl-
edge of cellular localization and molecular interactions
Table 1 Expression of the 5 multidrug resistance proteins









P-gp 30 4 18 8 0 26.67
Topo II 30 13 10 7 0 23.33
GST-π 30 10 15 5 0 16.67
MRP 30 28 1 1 0 3.33
LRP 30 26 3 1 0 3.33
In tumor cells, the strongly positive rate of P-gp, Topo II, GST-π, LRP and MRP
were 26.67%,23.33%,16.67%,3.33% and 3.33%, respectively. This difference
was statistically significant (Rank sum test, P < 0.05)
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here indicate that P-gp is mainly expressed in the
endothelial cells lining and surrounding small vessels, in
which the transporter appears concentrated within the
luminal cellular compartment. LRP, MRP, GST-π and
Topo II are not expressed in the capillary vessels and
are partly expressed in the interstitium. In order to
identify the exact location of P-gp in the capillary ves-
sels, immunostaining for S-100 protein was simulta-
neously performed. S-100 is expressed in glial and
Schwann cells but is not expressed in capillary endothe-
lial cells and basement membrane. Our results confirm
that P-gp is located in the end-feet of glial cells. There
were two pieces of evidence to support this. One, S-100
was observed in capillary vessels, and the localization of
S-100 was similar to that of P-gp. Two, the localization
of S-100 was consistent with P-gp localization in the
interstitial tissue. In the intracranial region, most of the
glial cells are astrocytes, and P-gp is located in the end-
f e e to ft h ea s t r o c y t e s .T h e s ed a t ac o n f i r ma ne f f e c t i v e
role of endothelial P-gp as a “gatekeeper” in the BBB
that limits the influx of drugs in the brain and indicate
the pericytes as a possible second line of defense at BBB
sites[13]. So, whether before the drugs through the BBB
or during the drugs through the BBB, P-gp has played
an important role in multidrug resistant. In this study,
we found that there was no difference in the expression
of multidrug resistance proteins between different
degrees of malignancy of brain tumor cells. However,
there were significant differences in expression of these
proteins in the capillary vessels, which suggests that the
expression of multidrug resistance proteins in the capil-
lary vessels is potentially the main reason for differential
resistance in brain tumors with differing malignancies.
Our study also demonstrated that the expression of
P-gp in the interstitial cells was related to the distance
of the cells from the capillary wall. The nearer the cell
was to the capillary wall, the stronger the expression of
P-gp. That is, where there were a large number of
tumor cells but no capillaries, no expression of P-gp in
tumor cells and the interstitium was observed, which
shows that the multidrug resistance of brain tumors
mainly occurs in and around the capillaries and is
related to the distance from capillaries.
Currently, part of the research on P-gp is focused on
its localization in caveolae [14]. Caveolae are flask-
shaped, invaginated membranes enriched in cholesterol
and sphingomyelin, which confer particular physico-
chemical properties including insolubility in anionic
detergents and low-buoyant density in sucrose gradients
[15-17]. These microdomains are present in a wide vari-
ety of cell types and are dynamic structures involved in
Figure 1 The expression of P-gp and S-100 in brain tumors (astrocytoma),(×400). (a, b, c) The expression of P-gp is weak in tumor cells
(red arrow), but strongly positive in capillary vessels (black arrow). (c) The expression of P-gp in the interstitial cells was related to the distance
from the capillary wall. The expression of P-gp was stronger the nearer the cell was to the capillary wall (green arrow). (d) The expression of S-
100 in brain tumors. Our study shows the expression of P-gp and S-100 are co- localized in the capillary endothelial cells and interstitial cells of
tumor tissues. These findings suggest P-gp expression at the microvasculature is found at both the endothelium as well at the astrocyte end-
feet at the microvasculature.
Table 2 Expression of the 5 multidrug resistance proteins









P-gp 30 3 6 12 9 70.00
Topo II 30 23 5 2 0 6.67
GST-π 30 26 3 1 0 3.33
MRP 30 27 2 1 0 3.33
LRP 30 27 3 0 0 0.00
The expression of P-gp is strongly positive in capillary vessels. Low positive
expression of LRP, MRP, GST-π and Topo II was observed in capillary vessels.
This difference was statistically significant (Rank sum test, P < 0.01)
Table 3 Expression of the 5 multidrug resistance proteins









P-gp 30 3 13 10 4 46.67
Topo II 30 21 3 2 4 20.00
GST-π 30 13 14 2 1 10.00
MRP 30 24 4 1 1 6.67
LRP 30 22 6 1 1 6.67
The expression of resistance proteins in interstitial cells are similar to the
tumor cells. The positive expression of P-gp is highest, the difference was
statistically significant (Rank sum test, P < 0.05)
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Caveolin-1, one of the major structural protein of caveo-
lae, co-localizes with P-gp in fractions of rat brain capil-
laries [11]. The expression of both P-gp and caveolin-1
is increased when cellular plasma membrane caveolae
are increased [19,20]. Furthermore, by immunoprecipita-
tion and immunofluorescence laser scanning confocal
microscopy experiments, caveolin-1 has been demon-
strated to physically interact with P-gp in the microvas-
cular endothelium and at the extensive networks of
astrocytic processes [11,21]. However, in brain tumors,
there are few reports about the interaction between
P-gp and caveolin-1.
The data reported in this study on the co-localization
of P-gp with caveolin-1 provide the morphological evi-
dence of the association between P-gp and caveolin-1 in
brain tumor endothelia and highlight the dynamic nat-
ure of this interaction. For the studies on caveolin-1 and
P-gp distribution and colocalization, major points have
to be considered. The studies use immunolabeling of
brain tissues with antibodies against P-gp and caveolin-
1, and evidence was found for the expression of P-gp on
the luminal membrane of the capillary endothelium in
brain tumors. However, caveolin-1 is expressed on the
entire thickness of the endothelium from the luminal to
the abluminal side. P-gp and caveolin-1 appear to largely
co-localize in the luminal compartment of the endothe-
lial cells, and co-localizati o ni sd e t e c t a b l eo n l ya tt h e
boundary between the luminal and abluminal endothe-
lial cell compartments. A previous study demonstrated
that only a portion of P-gp molecules [11] are associated
with caveolin-1, which suggests that different cell phe-
notypes may modify the localization of P-gp and caveo-
lin-1, and different cellular events may lead to
redistribution of both proteins.
In summary, the present study indicates that P-gp
is mainly expressed in capillary endothelial cells and
Table 4 Positive expression of the 5 multidrug resistance








n 1 02 0- 1 02 0- 1 02 0-
P-gp 4 3 0.378 6 2 0.027 8 19 0.251
Popo 4 4 0.384 0 0 - 0 0 -
GST 3 2 0.3 0 0 - 8 14 0.682
MRP 0 0 - 0 0 - 2 2 0.584
LRP 0 0 - 0 0 - 2 2 0.584
In tumor cells and interstitial cells, there was no significant difference
between the expression of the 5 multidrug resistance proteins (Fisher definite
probability methods, P > 0.05) between high grade and low grade tumors. In
the capillary vessels, the strong positive expression of P-gp was 60% (6/10) in
high grade and 10% (2/20) in low grade tumors. This difference was
statistically significant (Fisher definite probability methods, P < 0.05).
Figure 2 Immune co-labeling of P-gp/caveolin-1 in capillary endothelial cells. (×40 ×2 zoom). (a, e) Nuclear staining. (b, f) P-gp labeling
appears concentrated in the luminal compartment of the endothelial cells. (c, g) Caveolin-1 stains the entire endothelial cytoplasm with fine
puncta in the luminal compartment and larger, intensely immunoreactive puncta in the abluminal compartment. (d, h) The merged images
show P-gp and caveolin-1 co-expression (yellowish fluorescence). the two proteins co-localize either in the luminal endothelial compartment (d,
arrow) or at the border of the luminal/abluminal compartments (h, arrow).
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blood brain barrier, plays a significant role in brain
tumor resistance. In addition, the expression of P-gp in
the interstitial cells was related to the distance of the
cells from the capillary wall. The nearer the cell was to
the capillary wall, the stronger the expression of P-gp.
In the brain, the expression of P-gp and caveolin-1 was
found at both the end-feet of astrocytes and microvascu-
lar endothelium. The parallel expression of P-gp and
caveolin-1 supports the hypothesis that these two trans-
porter proteins may work in concert to mediate trans-
port processes in the brain at several levels, including
the microvascular endothelium, the microvascular astro-
cytic end-feet, and parenchymal astrocytic processes.
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